Downregulation of Hsa-miR-132 and Hsa-miR-129: Non-coding RNA Molecular Signatures of Alzheimer's Disease

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2024 Jul 10

PMID 38984196

Authors

Siranjeevi Nagaraj

Carolina Quintanilla-Sanchez

Kunie Ando

Lidia Lopez-Gutierrez

Emilie Doeraene

Andreea-Claudia Kosa

Emmanuel Aydin

Jean-Pierre Brion

Karelle Leroy

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) affects the elderly population by causing memory impairments, cognitive and behavioral abnormalities. Currently, no curative treatments exist, emphasizing the need to explore therapeutic options that modify the progression of the disease. MicroRNAs (miRNAs), as non-coding RNAs, demonstrate multifaceted targeting potential and are known to be dysregulated in AD pathology. This mini review focuses on two promising miRNAs, hsa-miR-132 and hsa-miR-129, which consistently exhibit differential regulation in AD. By employing computational predictions and referencing published RNA sequencing dataset, we elucidate the intricate miRNA-mRNA target relationships associated with hsa-miR-132 and hsa-miR-129. Our review consistently identifies the downregulation of hsa-miR-132 and hsa-miR-129 in AD brains as a non-coding RNA molecular signature across studies conducted over the past 15 years in AD research.

References

Idda M, Munk R, Abdelmohsen K, Gorospe M . Noncoding RNAs in Alzheimer's disease. Wiley Interdiscip Rev RNA. 2018; 9(2). PMC: 5847280. DOI: 10.1002/wrna.1463. View

Lau P, Bossers K, Janky R, Salta E, Sala Frigerio C, Barbash S . Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med. 2013; 5(10):1613-34. PMC: 3799583. DOI: 10.1002/emmm.201201974. View

Weinberg R, Mufson E, Counts S . Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Front Neurosci. 2015; 9:430. PMC: 4633499. DOI: 10.3389/fnins.2015.00430. View

Rajman M, Metge F, Fiore R, Khudayberdiev S, Aksoy-Aksel A, Bicker S . A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapses. EMBO J. 2017; 36(12):1770-1787. PMC: 5470041. DOI: 10.15252/embj.201695748. View

Patrick E, Rajagopal S, Wong H, McCabe C, Xu J, Tang A . Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer's disease. Mol Neurodegener. 2017; 12(1):51. PMC: 5494142. DOI: 10.1186/s13024-017-0191-y. View

Bartel D . Metazoan MicroRNAs. Cell. 2018; 173(1):20-51. PMC: 6091663. DOI: 10.1016/j.cell.2018.03.006. View

Glenner G, Wong C . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120(3):885-90. DOI: 10.1016/s0006-291x(84)80190-4. View

Nagaraj S, Want A, Laskowska-Kaszub K, Fesiuk A, Vaz S, Logarinho E . Candidate Alzheimer's Disease Biomarker miR-483-5p Lowers TAU Phosphorylation by Direct ERK1/2 Repression. Int J Mol Sci. 2021; 22(7). PMC: 8037306. DOI: 10.3390/ijms22073653. View

Lee S, Chu K, Jung K, Ban J, Im W, Jo H . Altered expression of miR-202 in cerebellum of multiple-system atrophy. Mol Neurobiol. 2014; 51(1):180-6. DOI: 10.1007/s12035-014-8788-4. View

10.

Min S, Sohn P, Li Y, Devidze N, Johnson J, Krogan N . SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. J Neurosci. 2018; 38(15):3680-3688. PMC: 5895994. DOI: 10.1523/JNEUROSCI.2369-17.2018. View

11.

Dobricic V, Schilling M, Schulz J, Zhu L, Zhou C, Fuss J . Differential microRNA expression analyses across two brain regions in Alzheimer's disease. Transl Psychiatry. 2022; 12(1):352. PMC: 9424308. DOI: 10.1038/s41398-022-02108-4. View

12.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

13.

Alieva A, Filatova E, Karabanov A, Illarioshkin S, Limborska S, Shadrina M . miRNA expression is highly sensitive to a drug therapy in Parkinson's disease. Parkinsonism Relat Disord. 2014; 21(1):72-4. DOI: 10.1016/j.parkreldis.2014.10.018. View

14.

Hadar A, Milanesi E, Walczak M, Puzianowska-Kuznicka M, Kuznicki J, Squassina A . SIRT1, miR-132 and miR-212 link human longevity to Alzheimer's Disease. Sci Rep. 2018; 8(1):8465. PMC: 5981646. DOI: 10.1038/s41598-018-26547-6. View

15.

Chen-Plotkin A, Unger T, Gallagher M, Bill E, Kwong L, Volpicelli-Daley L . TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci. 2012; 32(33):11213-27. PMC: 3446826. DOI: 10.1523/JNEUROSCI.0521-12.2012. View

16.

Zhu Q, Unmehopa U, Bossers K, Hu Y, Verwer R, Balesar R . MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease. Brain. 2016; 139(Pt 3):908-21. DOI: 10.1093/brain/awv383. View

17.

Yoon S, Kim S, Ko Y, Jeong G, Lee K, Lee J . Differential expression of MicroRNAs in Alzheimer's disease: a systematic review and meta-analysis. Mol Psychiatry. 2022; 27(5):2405-2413. DOI: 10.1038/s41380-022-01476-z. View

18.

Zhang M, Bian Z . Alzheimer's Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. Front Neurosci. 2021; 15:687973. PMC: 8180577. DOI: 10.3389/fnins.2021.687973. View

19.

Annese A, Manzari C, Lionetti C, Picardi E, Horner D, Chiara M . Whole transcriptome profiling of Late-Onset Alzheimer's Disease patients provides insights into the molecular changes involved in the disease. Sci Rep. 2018; 8(1):4282. PMC: 5844946. DOI: 10.1038/s41598-018-22701-2. View

20.

Wakabayashi K, Mori F, Kakita A, Takahashi H, Tanaka S, Utsumi J . MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples. Neurosci Lett. 2016; 635:117-122. DOI: 10.1016/j.neulet.2016.10.034. View